Wall Street brokerages expect that Chemed Co. (NYSE:CHE) will report $423.56 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Chemed’s earnings, with estimates ranging from $421.72 million to $425.40 million. Chemed posted sales of $403.48 million in the same quarter last year, which suggests a positive year-over-year growth rate of 5%. The firm is expected to issue its next quarterly earnings report after the market closes on Wednesday, February 14th.

According to Zacks, analysts expect that Chemed will report full year sales of $423.56 million for the current fiscal year. For the next fiscal year, analysts forecast that the business will report sales of $1.73 billion per share, with estimates ranging from $1.69 billion to $1.76 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Chemed.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. Chemed had a net margin of 4.62% and a return on equity of 27.69%. The business’s revenue was up 6.3% on a year-over-year basis. During the same period last year, the firm posted $1.73 earnings per share.

Several analysts recently commented on CHE shares. TheStreet raised shares of Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Zacks Investment Research raised shares of Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price for the company in a research note on Thursday, November 2nd. ValuEngine lowered shares of Chemed from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. KeyCorp reissued a “hold” rating on shares of Chemed in a research note on Friday, October 27th. Finally, Royal Bank of Canada reissued a “hold” rating and set a $209.00 target price on shares of Chemed in a research note on Tuesday, October 3rd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Chemed has an average rating of “Hold” and an average price target of $236.00.

Chemed (NYSE:CHE) traded up $3.01 during trading on Thursday, hitting $266.44. 74,942 shares of the stock traded hands, compared to its average volume of 65,945. Chemed has a twelve month low of $163.50 and a twelve month high of $268.53. The company has a market capitalization of $4,253.98, a PE ratio of 59.21, a PEG ratio of 2.99 and a beta of 1.16. The company has a quick ratio of 0.48, a current ratio of 0.50 and a debt-to-equity ratio of 0.15.

In related news, VP Michael D. Witzeman sold 1,000 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $250.00, for a total transaction of $250,000.00. Following the completion of the sale, the vice president now directly owns 3,334 shares of the company’s stock, valued at $833,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Naomi C. Dallob sold 750 shares of the stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $222.09, for a total transaction of $166,567.50. Following the sale, the vice president now directly owns 9,097 shares of the company’s stock, valued at $2,020,352.73. The disclosure for this sale can be found here. Over the last three months, insiders have sold 45,679 shares of company stock valued at $10,628,959. Company insiders own 4.90% of the company’s stock.

Several large investors have recently modified their holdings of CHE. Victory Capital Management Inc. lifted its position in shares of Chemed by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 1,434 shares of the company’s stock valued at $293,000 after acquiring an additional 216 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Chemed by 12.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after acquiring an additional 83 shares in the last quarter. Swiss National Bank lifted its position in shares of Chemed by 1.5% in the 2nd quarter. Swiss National Bank now owns 27,200 shares of the company’s stock valued at $5,563,000 after acquiring an additional 400 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Chemed by 45.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 86,314 shares of the company’s stock valued at $17,653,000 after acquiring an additional 27,027 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Chemed by 0.6% in the 2nd quarter. Wells Fargo & Company MN now owns 68,004 shares of the company’s stock valued at $13,909,000 after acquiring an additional 406 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/21/423-56-million-in-sales-expected-for-chemed-co-che-this-quarter.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Get a free copy of the Zacks research report on Chemed (CHE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.